Both lead to an increased ACE2 activity.42 The drugs may alleviate inflammation, decrease endothelial dysfunction and increase insulin sensitivity.29 The ARBs have more potential to block the RAS than ACEI, as about 40% of angiotensin II is formed via non-ACE pathways in humans.29 ARBs are known to have less side-effects than ACE inhibitors. The gene discussed is ACE2; the disease is endothelial dysfunction.